ADP Canada Pay Insights shows job-stayer base pay rises 3.0% in September
Bitget2026/10/08 12:15ADP Canada Pay Insights showed job-stayers’ median annual base pay rose 3.0% year over year in September 2026. Job-changers recorded a 5.6% median annual base pay gain, signalling a wider premium for switching employers. Gross pay growth ran hotter, rising 4.4% for job-stayers, with job-changers up 9.9%. Sector results clustered near 3.0%-3.2%, with manufacturing at 3.2%. Provincial readings ranged from 2.5% in Yukon to 4.1% in Prince Edward Island. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADP - Automatic Data Processing Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202610080815CANADANWCANADAPR_C3767) on October 08, 2026, and is solely responsible for the information contained therein.
- ADP Canada Pay Insights showed job-stayers’ median annual base pay rose 3.0% year over year in September 2026.
- Job-changers recorded a 5.6% median annual base pay gain, signalling a wider premium for switching employers.
- Gross pay growth ran hotter, rising 4.4% for job-stayers, with job-changers up 9.9%.
- Sector results clustered near 3.0%-3.2%, with manufacturing at 3.2%.
- Provincial readings ranged from 2.5% in Yukon to 4.1% in Prince Edward Island.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
